Physician profile
Mahdi Taha
NPI 1346488061
$1,682,610.06
in general payments reported to CMS, 2019-2025
84 companies · $452K in 2025
The $452K reported for 2025 was more than what 99% of Medical Oncology providers received nationally (typical 2025 total: $1,158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $145K · 2020: $69K · 2021: $169K · 2022: $234K · 2023: $298K · 2024: $317K · 2025: $452K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $619K · Travel and Lodging: $170K · Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $154K · Consulting Fee: $80K · Food and Beverage: $39K · Honoraria: $3,925 · Education: $541.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $618,849.74 |
| Travel and Lodging | $170,315.30 |
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $153,598.75 |
| Consulting Fee | $80,441.61 |
| Food and Beverage | $38,833.64 |
| Honoraria | $3,925.00 |
| Education | $540.74 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $554,815.27 | 2019-2025 | Rybrevant, Erleada, Carvykti |
| Eisai INC. | $410,077.63 | 2019-2025 | |
| Astrazeneca Pharmaceuticals Lp | $164,406.75 | 2019-2025 | Lynparza, Imfinzi, Tagrisso |
| Seagen INC. | $66,914.97 | 2019-2023 | Tukysa, Padcev, Tivdak |
| Merck Sharp & Dohme LLC | $65,132.44 | 2019-2025 | Keytruda, Lynparza, Welireg |
| Regeneron Healthcare Solutions, INC. | $64,648.87 | 2019-2025 | Libtayo |
| Astellas Pharma US INC | $56,991.43 | 2019-2025 | Xtandi, Padcev, Xospata |
| Pfizer INC. | $55,529.13 | 2019-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $42,145.50 | 2019-2025 | Alunbrig, Fruzaqla, Iclusig |
| Exelixis INC. | $38,875.24 | 2019-2025 | Cabometyx |
| Dendreon Pharmaceuticals LLC | $37,487.62 | 2021-2025 | Provenge |
| Array Biopharma INC | $27,888.53 | 2019-2025 | Braftovi, Lorbrena, Mektovi |
| E.R. Squibb & Sons, L.L.C. | $20,815.29 | 2019-2025 | Opdivo, Krazati, Opdualag |
| Mirati Therapeutics, INC. | $15,948.05 | 2023 | Krazati |
| Bayer Healthcare Pharmaceuticals INC. | $9,768.62 | 2019-2025 |
Show all 84 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $9,108.65 | 2019-2025 | Piqray, Kisqali |
| Genzyme Corporation | $7,324.11 | 2019-2024 | |
| Janssen Pharmaceuticals, INC | $6,996.83 | 2023-2024 | Erleada, Darzalex, Talvey |
| Novocure INC. | $4,100.27 | 2019-2025 | Optune Lua (Novottf-200t), Optune |
| Amgen INC. | $3,698.45 | 2019-2023 | Lumakras |
| Partner Therapeutics, INC. | $3,631.71 | 2025 | Bizengri |
| Avyxa Pharma, LLC | $3,333.35 | 2025 | |
| Taiho Oncology, INC. | $1,531.26 | 2019-2024 | |
| Jazz Pharmaceuticals INC. | $1,506.36 | 2020-2025 | |
| Janssen Scientific Affairs, LLC | $1,010.00 | 2021 | |
| Epizyme, INC. | $994.18 | 2021 | |
| Genentech USA, INC. | $507.63 | 2019-2025 | Tecentriq, Polivy, Phesgo |
| Verity Pharmaceuticals INC. | $500.00 | 2024 | Trelstar |
| Celgene Corporation | $427.09 | 2019-2024 | Reblozyl, Opdualag |
| Daiichi Sankyo INC. | $401.54 | 2020-2024 | Enhertu |
| Ipsen Biopharmaceuticals, INC | $363.21 | 2019-2025 | Onivyde, Somatuline Depot, Tazverik |
| Lilly USA, LLC | $348.48 | 2021-2025 | Verzenio, Jaypirca, Retevmo |
| Glaxosmithkline, LLC. | $344.61 | 2021-2025 | Zejula, Jemperli, Ojjaara |
| Sirtex Medical INC | $294.27 | 2022-2023 | Sir-Spheres Microspheres |
| Rigel Pharmaceuticals, INC. | $261.16 | 2021-2025 | Rezlidhia, Tavalisse, Gavreto |
| Aroa Biosurgery Incorporated | $255.27 | 2024 | |
| Incyte Corporation | $253.63 | 2020-2024 | Jakafi |
| Abbvie INC. | $253.08 | 2020-2025 | Venclexta |
| Tempus Ai, INC | $246.61 | 2024-2025 | Xt Cdx |
| Sobi, INC | $246.13 | 2022-2024 | |
| Emd Serono, INC. | $241.15 | 2019-2024 | Bavencio |
| Servier Pharmaceuticals LLC | $210.20 | 2021-2025 | |
| Puma Biotechnology, INC. | $207.10 | 2020-2025 | |
| Adaptive Biotechnologies Corporation | $204.51 | 2022-2024 | Clonoseq |
| Novocure Gmbh | $200.00 | 2022 | |
| Beigene USA, INC. | $185.31 | 2022-2024 | Brukinsa, Tevimbra |
| Kyowa Kirin, INC. | $175.27 | 2019-2024 | Poteligeo |
| Boehringer Ingelheim Pharmaceuticals, INC. | $152.38 | 2019-2025 | |
| Tersera Therapeutics LLC | $139.22 | 2021-2024 | Zoladex |
| Pharmacyclics LLC, An Abbvie Company | $115.47 | 2020-2023 | Imbruvica |
| Myriad Genetic Laboratories, INC. | $108.75 | 2021-2024 | Precisetumor, Myrisk |
| Sanofi-Aventis U.S. LLC | $99.95 | 2019 | |
| Deciphera Pharmaceuticals INC. | $88.43 | 2021-2024 | Qinlock |
| Medtronic, INC. | $84.51 | 2022-2025 | Synchromedii |
| Stemline Therapeutics INC. | $71.68 | 2023-2024 | Orserdu |
| Acceleron Pharma, INC. | $71.50 | 2021 | |
| Pharmacosmos Therapeutics INC. | $63.40 | 2024 | Monoferric |
| Dova Pharmaceuticals | $60.80 | 2020-2021 | |
| Aveo Pharmaceuticals, INC. | $58.50 | 2023-2024 | Fotivda |
| Foundation Medicine, INC. | $55.90 | 2020-2022 | |
| Morphosys, US INC. | $50.54 | 2021 | |
| Alexion Pharmaceuticals, INC. | $49.83 | 2024 | Ultomiris |
| Legend Biotech USA INC. | $42.67 | 2024-2025 | Carvykti |
| Ferring Pharmaceuticals INC. | $40.62 | 2020-2024 | Adstiladrin |
| Secura Bio, INC. | $40.52 | 2021-2024 | Copiktra |
| Azurity Pharmaceuticals, INC. | $39.66 | 2024 | Vivimusta |
| Agios Pharmaceuticals, INC. | $36.56 | 2023 | Pyrukynd |
| Boston Scientific Corporation | $31.73 | 2022 | |
| Fresenius Kabi USA, LLC | $30.17 | 2024 | Stimufend |
| Sumitomo Pharma America, INC. | $27.40 | 2025 | Orgovyx |
| Blue Earth Diagnostics | $23.83 | 2023 | |
| Immunogen, INC. | $23.28 | 2023 | Elahere |
| Cumberland Pharmaceuticals, INC. | $20.55 | 2023 | Sancuso |
| Kite Pharma, INC. | $20.42 | 2022 | |
| Tg Therapeutics, INC. | $19.25 | 2021 | |
| Clovis Oncology, INC. | $19.19 | 2022 | |
| Octapharma USA, INC. | $18.49 | 2023 | Panzyga |
| Adc Therapeutics America, INC. | $17.03 | 2025 | |
| Heron Therapeutics, INC. | $16.05 | 2021 | |
| Tolmar Pharmaceuticals, INC. | $13.89 | 2021 | |
| Springworks Therapeutics, INC. | $13.12 | 2024 | |
| Organon LLC | $12.99 | 2023 | Ontruzant |
| Gilead Sciences, INC. | $12.88 | 2021 | |
| Macrogenics, INC. | $12.14 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mahdi Taha listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.